Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.955
-0.055 (-5.45%)
Apr 29, 2026, 12:38 PM EDT - Market open
Valion Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
2.75M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.51M |
| Ensysce Biosciences | 5.07M |
| 60 Degrees Pharmaceuticals | 1.41M |
| VivoSim Labs | 142.00K |
| AIM ImmunoTech | 88.00K |
| Azitra | 7.50K |
VBIO News
- 1 day ago - VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME - PRNewsWire
- 5 days ago - Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model - PRNewsWire
- 14 days ago - Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th - PRNewsWire
- 27 days ago - Valion Bio Transcript: Emerging Growth Conference 91 - Transcripts
- 4 weeks ago - Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod - Accesswire
- 4 weeks ago - Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference - Accesswire
- 4 weeks ago - Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome - Accesswire
- 4 weeks ago - Valion Bio Earnings Call Transcript: Q4 2025 - Transcripts